Nascent Biotech, Inc.

Equities

NBIO

US63108Q1013

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 19:30:29 17/06/2024 BST			5-day change	1st Jan Change
0.09 ^USD	+3.46%		-6.93%	-47.95%

04-16	Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	CI
03-19	Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	CI

Nascent Biotech, Inc. Announces the Resignation of Mark Glassy as Officer and Director and Accepts the Position as Chairman of the Scientific Advisory Board

September 08, 2015 at 09:59 pm

Effective September 6, 2015, Mark Glassy resigned as an Officer and Director of Nascent Biotech Inc. and accepted the position as Chairman of the company's Scientific Advisory Board. Dr. Glassy will continue his relationship with the company in his new role as a consultant, along with advising the company on various scientific issues relating to the company's products.

Latest news about Nascent Biotech, Inc.

Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	04-16	CI
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	03-19	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	02-06	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	22/08/23	CI
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	18/08/23	CI
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	02/07/23	CI
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	29/06/23	CI
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement	30/05/23	CI
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials	28/02/23	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial	25/01/23	CI
Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer Trial	10/01/23	CI
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board	20/12/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22	CI
Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research	04/10/22	CI
Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer	13/09/22	CI
Nascent Biotech, Inc. announced that it has received $0.2425 million in funding from Platinum Point Capital LLC	07/09/22	CI
Nascent Biotech, Inc. announced that it expects to receive $1.5 million in funding from Yorkville Advisors Global LP	29/08/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	09/08/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	15/06/22	CI
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	14/06/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	04/11/21	CI

Chart Nascent Biotech, Inc.

Duration

Period

More charts

Company Profile

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NASCENT BIOTECH, INC.	-47.95%	15.35M
VERTEX PHARMACEUTICALS INCORPORATED	+16.42%	122B
REGENERON PHARMACEUTICALS, INC.	+19.02%	113B
ARGENX SE	+3.17%	22.66B
BIONTECH SE	-16.20%	21.34B
WUXI APPTEC CO., LTD.	-39.57%	16.92B
BEIGENE, LTD.	-11.63%	16.68B
GENMAB A/S	-16.17%	16.61B
NEUROCRINE BIOSCIENCES, INC.	+2.68%	13.62B
SAREPTA THERAPEUTICS, INC.	+21.16%	11.04B

Bio Therapeutic Drugs